Adherence to lipid-lowering drug therapy among members of the Canadian forces

Military Medicine

Volumn 173, Issue 7, 2008, Pages 666-670

  Ma, Janice ^a   Vaillancourt, Régis ^b   Bennett, Carol ^c  

^a National Defence Medical Centre   (Canada)

^b CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID;

ADULT; CANADA; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; FORCE; HEALTH CARE SYSTEM; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHARMACY; REVIEW; SOLDIER;

EID: 47749127295     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/MILMED.173.7.666     Document Type: Review

References (21)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al: For the West of Scotland Coronary Prevention Study Group: prevention of coronary heart disease in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
3. Downs JR, Clearfield M, Weis S, et al: For the AF-CAPSD/TexCAPS Research Group: primary prevention of acute coronary events, with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
4. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J: Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.
5. Jackevicius CA, Mamdami M, Tu JV: Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-7.
6. Tsuyuki RT, Johnson JA, Teo KK, et al: A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). Arch Intern Med 2002; 162: 1149-55.
7. Spaans JN, Coyle D, Fodor G, et al: Application of the 1998 Canadian cholesterol guidelines to a military population: health benefits and cost effectiveness of improved cholesterol management. Can J Cardiol 2003; 19: 790-6.
8. Moisan J, Vaillancourt R, Grégoire JP, Gaudet M, Côté I, Leach A: Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes. Am J Health Syst Pharm 1999; 56: 1437-41.
9. Vaillancourt R, Gutschi LM, Ma J, Sinclair S, Beechinor D: Pharmacist-managed lipid clinics: development and implementation in the Canadian Forces. Can J Hosp Pharm 2003; 56: 24-31.
10. Krueger KP, Berger BA, Felkey B: Medication adherence and persistence: a comprehensive review. Adv Ther 2005; 22: 313-56.
11. Jones I, Britten N: Why do some patients not cash their prescriptions? Br J Gen Pract 1998; 48: 903-5.
12. McElnay JC, McCallion CR, al-Deagi F, Scott M: Self-reported medication non-compliance in the elderly. Eur J Clin Pharmacol 1997; 53: 171-8.
13. Agarwal MR, Sharma VK, Kishore Kumar KV, Lowe D: Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998; 44: 92-106.
14. Yuan Y, L'italien G, Mukherjee J, Iloeje U: Determinants of discontinuation of initial highly active antiretroviral therapy regimens in a US HIV-infected patient cohort. HIV Med 2006; 7: 156-62.
15. Chisholm MA, Lance CE, Mulloy LL: Patient factors associated with adherence to immunosuppressant therapy in renal transplant recipients. Am J Health Syst Pharm 2005; 62: 1775-81.
16. Bayer, Inc.: Market withdrawal of Baycol (cerivastatin). Available at http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/2001/ baycol_2_hpc-cps_e.html; accessed March 10, 2006.
17. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee: Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003; 27(Suppl 2): S1-152.
18. Khan NA, McAlister FA, Lewanczuk RZ, et al: Canadian Hypertension Education Program: the 2005 Canadian Hypertension Education Program recommendations for the management of hypertension. Part II. Therapy. Can J Cardiol 2005; 21: 657-72.
19. International Diabetes Federation: The International Diabetes Federation consensus worldwide definition of the metabolic syndrome, 2005. Available at http://www.idf.org/home/index.cfm?unode=1120071E-AACE-41D2-9FA0-BAB6E25BA072; accessed March 14, 2006.
20. Stotland SC, Larocque M: Early treatment response as a predictor of ongoing weight loss in obesity treatment. Br J Health Psychol 2005; 10: 601-14.
21. Diabetes Prevention Program Research Group: Achieving weight and activity goals among Diabetes Prevention Program lifestyle participants. Obes Res 2004; 12: 1426-34.